Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics Oxford, UK, 6 November 2025 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), an immunology company tackling the root causes of […]
Leverages Kling’s technology to discover hard-to-find, immuno-functional antibodies from immortalized human B cells Accelerating discovery of first-in-class antibodies to transform disease prevention and treatment Amsterdam, NLD – 24 July 2025 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs for cancer and infectious diseases, today announced it has entered into a […]
Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]
Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]
Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]
